Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

Inclusion Criteria: * Hepatitis B surface antigen \[HBsAg\]-positive, * Either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative/hepatitis B e antibody (HBeAb)-positive disease were eligible, * Serum alanine aminotransferase (ALT) levels 3-10×the upper limit of normal (ULN),serum total bilirubin(TBIL)levels\<2×ULN Exclusion Criteria: * Co-infection with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus; * Other forms of liver disease; * More than 24 weeks of therapy with a nucleoside or nucleotide analog with activity against HBV, and therapy with any anti-HBV drug within 24 weeks prior to randomization; * More than 12 weeks of therapy with liver protectants, and therapy with glycyrrhizin; * Has decompensated liver function or has a hint of hepatocellular carcinoma (HCC); * During the study patients were not allowed to use other medicines.